Member Info for RayPointer

The science behind moditope is very clever but it has yet to be proved in the clinic. So only investors who understand the science would swoop in an pick up shares at bargain prices or perhaps people willing to take a gamble. The majority would see it as another failed baby bio going down the pan.
Another way of looking at it is taking note of all the eminent scientists outside of Scancell who want to be involved in some way.

Just extra confirmation that the scientific community is really interested in Moditope. 6 clinical professors willing to give up some of their time for little old Scancell. I'm going to start knitting Scancell scarves for all these supporters. Claret and blue of course.

"CH is said to have indicated there may well be further projects with BioNtech... what can that mean!!?"

Well we have 37 citrullinated targets and an unknown number of homocitrullinated targets, so I would guess it is all about expanding the scope of the current collaboration.

The original scope was for 2 targets only. No doubt the most important targets but there are more to choose from.

C7, I hope your op doesn't clash with the Chelsea match.
Good wishes from me

But, as you say, we still await a clinical trial, hopefully not too long now.
The trial itself is interesting in that it is aimed at 3 hard to treat cancers namely TNBC, ovarian and head and neck (previously the 3rd cancer was sarcoma)
The manufacturing problems have been sorted so Sally Adam's team should now be working on the toxicology report.

Meanwhile, the scientific side of the Biontech collaboration may conclude.
Biontech may want to strike a deal before modi1 initial trial results.

Hi Van
You are definitely on the right lines.
I stand to be corrected on anything below

1 the 37 refers to the number of citrullinated targets
2 we don't yet know how may homocitrullinated targets Lindy has found
3 both modi1and modi2 activate highly potent CD4 killer cells, as far as we know Scancell is the first bio to do this
4 only low penetration of the tumour environment is required. This is because a chain reaction is initiated that causes the tumour more stress, more autophagy and hence more citrullination
5 at the same time more clonal expansion is probably taking place creating more of the cd4 killer cells
6 the addition of amplivant to the vaccine acts as a catalyst enabling a much lower dose to be effective
7 Lindy believes that Moditope will not require help from a Checkpoint inhibitor
8 Lindy is excited that between them modi1 and modi2 will zap just about any cancer (she said this at the last AGM)

TF. Ashley Barnes was booked the other day for kissing an opposing defender. Did he learn this at TUFC?

The long awaited scib1 combo trial is at last underway. I personally don't think it matters whether we treat Brits or yanks. I believe we are physiologically the same. They will claim they have more balls than us lol.
Also good to know that Modi1 is progressing.
Maybe more news to come tonight.

Now let's show the world how good scib1 is. Sorry my rampometer is beeping.

Happy birthday to you C7.

Shame Chelsea did not win but then you were up against the mighty clarets!

https://www.amazon.co.uk/Dragon-Clear-Terrarium-Finishing-Effect/dp/B00CQ444C8

Sold out on amazon so must be good.

Ruck
I will let you off for a bag of sherbet lemons

Ruck., I disagree. There are never bugs in my programs.
I can send you the test results if you like. Can you send a lorry over to my place.

Ruck

A trillion lines is a trillion lines however it is produced.
So my lawyer advises me.
My highly complex program is going to make me very popular.

for (i=0;i<1000000000000;i++)
{
Print("I'm a dog with a bone");
}

Job done (I assume American trillion)

I looked back and this is Steve's post

After a bit of work, I think this has come out pretty well ... enjoy!

https://drive.google.com/file/d/12QRlLjAojWKukLipQ4_1MkpOZOUTjHoJ/view

The link is still available. Steve's post had 12 recs. I think it deserved more!

I refer to the recording that Steve67 posted after the AGM. I downloaded the recording at the time.
Probably best for you to look through Steve's posts to find it and hope that the link still exists.

It was on a publically available google drive.

I've just been listening to the AGM tape again.

At about 40.45 Lindy explains that if the tumour avoids citrullination it cannot avoid homocitrullination and vice versa.
She went on to say that, because of this, a combination of Modi1 and Modi2 could potentially zap any cancer cell.

She was talking quickly in typical Lindy fashion so I couldn't quite catch every word she said but I bet she was smiling when she said this.

"AMG319 is a PI3Kd inhibitor. Preclinically, target inhibition abrogates Treg mediated immunosuppression, augmenting CD8+ T-cell anti-tumour activity. "

The aim was to produce an inhibitor that would give the immune system a better chance of attacking the tumour. So the same basic aim as CIs like Keytruda but with a different target to inhibit.

As you say, crumbs, the trial does not appear to be going well.

Perhaps Scancell knew about this trial and decided to compete but I think inan's comment about the switch was probably more relevant. It is fine tuning as Scancell test Modi1 against more and more cancers in mice. Also perhaps, the work in the BionTech collaboration has some relevance to this.

I always get the impression that Lindy strives to produce vaccines that go after the most difficult cancers to treat. So there also might be an element of this too.

But it would be nice if CRUK wanted to do deals on Moditope trials with a similar framework to the SCIB2 trial.
You do see Nigel Blackburn's quote in you first link:

Dr Nigel Blackburn, CRUK’s director of drug development, said: “We’re delighted that the collaboration between Amgen and our Centre for Drug Development is moving into Phase II trials. It means we’re getting closer to providing a new treatment for cancer patients.

I wonder if he is also thinking:
"It would be better to be involved in Moditope trials"

Here's a similar document for Nivolumab in combination with ipilimumab for
treating advanced melanoma (June 2016)

https://www.nice.org.uk/guidance/ta400/documents/final-appraisal-determination-document

https://www.nice.org.uk/guidance/ta268/documents/melanoma-stage-iii-or-iv-ipilimumab-final-appraisal-determination-guidance2

I don't know if this is up to date (dated 2012) but it is interesting to see the costs of Yervoy at that time (see page 2)

" Ipilimumab costs
£3750 for 50 mg and £15,000 for 200 mg (excluding VAT, British
national formulary, September 2012). Assuming an average body
weight of 70 kg, each dose of ipilimumab would need a 200 mg vial
and a 50 mg vial costing £18,750. A 4-dose course would therefore
cost £75,000, not including administration costs. "